Immunity & good health is determined by the collective presence of living symbiotic, and pathogenic microorganisms in the human microbiome system. Throughout the life cycle age accordingly, bacterial community & its characteristics vary.
Nasal cavity mutualistic bacteria compete for space, and nutrients & produce toxic materials, helping repress pathogenic bacteria and inhibit or kill them. Nasal cavity dysbiosis leads to opportunistic pathogenic bacteria presence, spread in the respiratory tract & the development of allergic rhinitis (AR), chronic rhinosinusitis (CRS), acute respiratory tract infections (ARTI), otitis media (OM), and asthma.
CRS
Instigates disease progression, nasal polyps’ development, chronic symptoms, and sinus cavity inflammatory response. The prevalent presence of Coagulase-negative Staphylococcus, Pseudomonas aeruginosa, and S. aureus influence & modulate the immune response.
Determines asthma onset, advancement, acuteness, metagenomic inference & bacterial glycerolipid metabolism and increase in Prevotella buccalis, Gardnerella vaginalis, P. buccalis, G. vaginalis, Dialister invisus, and Alkanindiges hongkongensis species. Asymptomatic expansion of Streptococcus affects the future possibility, danger & later episodes of asthma and its inflammation symptoms.
In asthma-affected children, Moraxella, Staphylococcus, Corynebacterium, Haemophilus, Fusobacterium, Prevotella, and Dolosigranulum dominate the nasal microbiome environment.
Affects the immune response modulation, pathophysiology & AR growth. In seasonal allergic rhinitis (SAR) patients, pollination season spikes symptoms, nasal eosinophils levels & middle meatus bacterial biodiversity.
Controls host’s susceptibility, influenza-specific immunoglobulin A antibody production disparity, taxa richness rise & the surge of Streptococcus pneumoniae, S. aureus, Phyllobacterium, Moraxella, Staphylococcus, Corynebacterium, and Dolosigranulum in the nasal carriage.
Concomitantly S. pneumoniae transmission increases shooting up protease secretion, activates viral hemagglutinins and modulates the innate immune response. Facilitates influenza, A virus (adenovirus, or rhinovirus) infection & associated respiratory virus infection, S. pneumoniae elevation & invasive pneumococcal pneumonia risk.
Regulates Moraxella, Streptococcus, and Pasteurella spp migration from the middle ear to the nose microbiome & leading to OM. S. pneumoniae, Haemophilus, Actinomyces, Rothia, Neisseria, and Veillonella increase in OM-affected children. OM acute episodes escalate abundant increase of otopathogen genera and decrease in Pseudomonas, Myroides, Yersinia, and Sphingomonas.
The nasal passage is colonized with a diverse range of bacteria, fungi, and viruses and it is the first contact point to the external environment exposure. The nasal microbiota profile positively correlates with amplified immune response. Further research is required to reinforce the promising role of probiotic intervention in the supplementary treatment of nasal dysbiosis-connected respiratory infections.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Canine Cancer Vaccine: A Potential Resurrection? U.S. KK. Snubs Enertu.
2.
An Intimate Life of Medical Innovation and Charity.
3.
Decoding calcifications in breast cancer: Towards personalized medicine
4.
Could CT scans be fueling a future rise in cancer cases, as a new study suggests?
5.
Study: Pre-operative THP leads to pCR in 64% of early-stage HER2+ ER- breast cancer patients
1.
All You Need To Know About Cancer Antigen 27-29: Causes, Symptoms & Treatment
2.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
3.
Expanding Oncology Frontiers: Rare Cancers, Breakthroughs, and Precision Medicine Advances
4.
Revolutionizing Lung Cancer Treatment: Exploring the Benefits of Wedge Resection Surgery
5.
From Autoimmune Disorders to COVID-19: How Plasmapheresis Is Revolutionizing Modern Medicine
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation